Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan.

Monto AS, DeJonge P, Callear AP, Bazzi LA, Capriola S, Malosh RE, Martin ET, Petrie JG.

J Infect Dis. 2020 Apr 4. pii: jiaa161. doi: 10.1093/infdis/jiaa161. [Epub ahead of print]

PMID:
32246136
2.

Influenza B Viruses Exhibit Lower Within-Host Diversity than Influenza A Viruses in Human Hosts.

Valesano AL, Fitzsimmons WJ, McCrone JT, Petrie JG, Monto AS, Martin ET, Lauring AS.

J Virol. 2020 Feb 14;94(5). pii: e01710-19. doi: 10.1128/JVI.01710-19. Print 2020 Feb 14.

PMID:
31801858
3.

Influenza Vaccine Effectiveness in the Inpatient Setting; Evaluation of Potential Bias in the Test Negative Design by use of Alternate Control Groups.

Segaloff HE, Cheng B, Miller AV, Petrie JG, Malosh RE, Cheng C, Lauring AS, Lamerato L, Ferdinands JM, Monto AS, Martin ET.

Am J Epidemiol. 2019 Nov 1. pii: kwz248. doi: 10.1093/aje/kwz248. [Epub ahead of print]

PMID:
31673696
4.

HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy.

Gilbert PB, Fong Y, Juraska M, Carpp LN, Monto AS, Martin ET, Petrie JG.

BMC Infect Dis. 2019 May 22;19(1):453. doi: 10.1186/s12879-019-4049-5.

5.

Comparison of a frailty short interview to a validated frailty index in adults hospitalized for acute respiratory illness.

Petrie JG, Martin ET, Zhu Y, Wyatt DG, Kaniclides A, Ferdinands JM, Monto AS, Trabue C, Talbot HK.

Vaccine. 2019 Jun 27;37(29):3849-3855. doi: 10.1016/j.vaccine.2019.05.051. Epub 2019 May 18.

PMID:
31113675
6.

Improving Influenza Vaccine Effectiveness: Ways to Begin Solving the Problem.

Monto AS, Petrie JG.

Clin Infect Dis. 2019 Oct 30;69(10):1824-1826. doi: 10.1093/cid/ciz416. No abstract available.

PMID:
31102404
7.

Data resource profile: Household Influenza Vaccine Evaluation (HIVE) Study.

Monto AS, Malosh RE, Evans R, Lauring AS, Gordon A, Thompson MG, Fry AM, Flannery B, Ohmit SE, Petrie JG, Martin ET; HIVE Study Research Staff.

Int J Epidemiol. 2019 Aug 1;48(4):1040-1040g. doi: 10.1093/ije/dyz086. No abstract available.

8.

Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Petrie JG, Martin ET, Truscon R, Johnson E, Cheng CK, McSpadden EJ, Malosh RE, Lauring AS, Lamerato LE, Eichelberger MC, Ferdinands JM, Monto AS.

Vaccine. 2019 Feb 28;37(10):1284-1292. doi: 10.1016/j.vaccine.2019.01.055. Epub 2019 Feb 7.

9.

Effects of Sequential Influenza A(H1N1)pdm09 Vaccination on Antibody Waning.

Zelner J, Petrie JG, Trangucci R, Martin ET, Monto AS.

J Infect Dis. 2019 Jun 5;220(1):12-19. doi: 10.1093/infdis/jiz055.

PMID:
30722022
10.

Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season.

Levine MZ, Martin ET, Petrie JG, Lauring AS, Holiday C, Jefferson S, Fitzsimmons WJ, Johnson E, Ferdinands JM, Monto AS.

J Infect Dis. 2019 May 24;219(12):1904-1912. doi: 10.1093/infdis/jiz049.

PMID:
30721982
11.

Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans.

Christensen SR, Toulmin SA, Griesman T, Lamerato LE, Petrie JG, Martin ET, Monto AS, Hensley SE.

J Virol. 2019 Apr 3;93(8). pii: e02134-18. doi: 10.1128/JVI.02134-18. Print 2019 Apr 15.

12.

Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons.

Havers FP, Hicks LA, Chung JR, Gaglani M, Murthy K, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Flannery B, Fry AM.

JAMA Netw Open. 2018 Jun 1;1(2):e180243. doi: 10.1001/jamanetworkopen.2018.0243.

13.

Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017.

Havers FP, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, Fry AM, Flannery B.

Clin Infect Dis. 2019 May 2;68(10):1616-1622. doi: 10.1093/cid/ciy780.

14.

Sera from Individuals with Narrowly Focused Influenza Virus Antibodies Rapidly Select Viral Escape Mutations In Ovo.

Davis AKF, McCormick K, Gumina ME, Petrie JG, Martin ET, Xue KS, Bloom JD, Monto AS, Bushman FD, Hensley SE.

J Virol. 2018 Sep 12;92(19). pii: e00859-18. doi: 10.1128/JVI.00859-18. Print 2018 Oct 1.

15.

Influenza A(H7N9) Virus Evolution: Which Genetic Mutations Are Antigenically Important?

Petrie JG, Lauring AS.

J Infect Dis. 2019 Jan 1;219(1):3-5. doi: 10.1093/infdis/jiy409. No abstract available.

PMID:
29982612
16.

Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016.

Segaloff HE, Petrie JG, Malosh RE, Cheng CK, McSpadden EJ, Ferdinands JM, Lamerato L, Lauring AS, Monto AS, Martin ET.

Epidemiol Infect. 2018 Aug;146(11):1350-1358. doi: 10.1017/S0950268818001486. Epub 2018 Jun 8.

17.

Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain.

Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE.

Vaccine. 2018 Jun 27;36(28):4095-4101. doi: 10.1016/j.vaccine.2018.05.086. Epub 2018 May 31.

18.

Multimorbidity is associated with uptake of influenza vaccination.

Harrison SM, Wei MY, Lamerato LE, Petrie JG, Toth Martin E.

Vaccine. 2018 Jun 14;36(25):3635-3640. doi: 10.1016/j.vaccine.2018.05.021. Epub 2018 May 7.

19.

Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines.

Petrie JG, Gordon A.

Vaccines (Basel). 2018 Mar 26;6(2). pii: E17. doi: 10.3390/vaccines6020017. Review.

20.

Maximum likelihood estimation of influenza vaccine effectiveness against transmission from the household and from the community.

Ainslie KEC, Haber MJ, Malosh RE, Petrie JG, Monto AS.

Stat Med. 2018 Mar 15;37(6):970-982. doi: 10.1002/sim.7558. Epub 2017 Nov 28.

21.

The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.

Petrie JG, Malosh RE, Cheng CK, Ohmit SE, Martin ET, Johnson E, Truscon R, Eichelberger MC, Gubareva LV, Fry AM, Monto AS.

Clin Infect Dis. 2017 Oct 30;65(10):1644-1651. doi: 10.1093/cid/cix608.

22.

Respiratory syncytial virus hospitalization in middle-aged and older adults.

Malosh RE, Martin ET, Callear AP, Petrie JG, Lauring AS, Lamerato L, Fry AM, Ferdinands J, Flannery B, Monto AS.

J Clin Virol. 2017 Nov;96:37-43. doi: 10.1016/j.jcv.2017.09.001. Epub 2017 Sep 7.

23.

Prior-Season Vaccination and Risk of Influenza During the 2014-2015 Season in the United States.

Chung JR, Flannery B, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Petrie JG, Martin ET, Monto AS, McLean HQ, Belongia EA, Gaglani M, Fry AM.

J Infect Dis. 2017 Jul 15;216(2):284-285. doi: 10.1093/infdis/jix286. No abstract available.

24.

Application of an Individual-Based Transmission Hazard Model for Estimation of Influenza Vaccine Effectiveness in a Household Cohort.

Petrie JG, Eisenberg MC, Ng S, Malosh RE, Lee KH, Ohmit SE, Monto AS.

Am J Epidemiol. 2017 Dec 15;186(12):1380-1388. doi: 10.1093/aje/kwx217.

25.

Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.

Petrie JG, Monto AS.

J Infect Dis. 2017 Mar 15;215(6):841-843. doi: 10.1093/infdis/jix056. No abstract available.

PMID:
28453852
26.

The Doctrine of Original Antigenic Sin: Separating Good From Evil.

Monto AS, Malosh RE, Petrie JG, Martin ET.

J Infect Dis. 2017 Jun 15;215(12):1782-1788. doi: 10.1093/infdis/jix173. Review.

27.

Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses.

Debbink K, McCrone JT, Petrie JG, Truscon R, Johnson E, Mantlo EK, Monto AS, Lauring AS.

PLoS Pathog. 2017 Jan 31;13(1):e1006194. doi: 10.1371/journal.ppat.1006194. eCollection 2017 Jan.

28.

Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains.

Petrie JG, Parkhouse K, Ohmit SE, Malosh RE, Monto AS, Hensley SE.

J Infect Dis. 2016 Dec 15;214(12):1947-1951. Epub 2016 Oct 7.

29.

2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.

Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B; US Flu VE Investigators; U.S. Flu VE Investigators.

Clin Infect Dis. 2016 Dec 15;63(12):1564-1573. Epub 2016 Oct 4.

30.

Influenza Vaccine Effectiveness Against Antigenically Drifted Influenza Higher Than Expected in Hospitalized Adults: 2014-2015.

Petrie JG, Ohmit SE, Cheng CK, Martin ET, Malosh RE, Lauring AS, Lamerato LE, Reyes KC, Flannery B, Ferdinands JM, Monto AS.

Clin Infect Dis. 2016 Oct 15;63(8):1017-25. doi: 10.1093/cid/ciw432. Epub 2016 Jul 1.

PMID:
27369320
31.

Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.

Petrie JG, Ohmit SE, Truscon R, Johnson E, Braun TM, Levine MZ, Eichelberger MC, Monto AS.

J Infect Dis. 2016 Oct 15;214(8):1142-9. doi: 10.1093/infdis/jiw105. Epub 2016 Apr 19.

PMID:
27095420
32.

Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.

Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Petrie JG, Ohmit SE, Monto AS, McLean HQ, Belongia EA, Fry AM, Flannery B.

J Infect Dis. 2016 May 15;213(10):1546-56. doi: 10.1093/infdis/jiv577. Epub 2016 Jan 6.

33.

Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine.

Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM.

Pediatrics. 2016 Feb;137(2):e20153279. doi: 10.1542/peds.2015-3279. Epub 2016 Jan 5.

34.

Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses.

Thompson MG, Clippard J, Petrie JG, Jackson ML, McLean HQ, Gaglani M, Reis EC, Flannery B, Monto AS, Jackson L, Belongia EA, Murthy K, Zimmerman RK, Thaker S, Fry AM.

Pediatr Infect Dis J. 2016 Mar;35(3):299-308. doi: 10.1097/INF.0000000000001006.

35.

Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated.

Ohmit SE, Petrie JG, Malosh RE, Johnson E, Truscon R, Aaron B, Martens C, Cheng C, Fry AM, Monto AS.

J Infect Dis. 2016 Apr 15;213(8):1229-36. doi: 10.1093/infdis/jiv563. Epub 2015 Nov 23.

36.

Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013.

Petrie JG, Cheng C, Malosh RE, VanWormer JJ, Flannery B, Zimmerman RK, Gaglani M, Jackson ML, King JP, Nowalk MP, Benoit J, Robertson A, Thaker SN, Monto AS, Ohmit SE.

Clin Infect Dis. 2016 Feb 15;62(4):448-455. doi: 10.1093/cid/civ952. Epub 2015 Nov 12.

37.

Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.

Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS.

J Infect Dis. 2015 Dec 15;212(12):1914-22. doi: 10.1093/infdis/jiv313. Epub 2015 May 26.

38.

Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.

Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE.

J Infect Dis. 2015 Oct 15;212(8):1191-9. doi: 10.1093/infdis/jiv195. Epub 2015 Apr 8.

PMID:
25858957
39.

Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season.

Havers F, Flannery B, Clippard JR, Gaglani M, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Eng HF, Lamerato L, Campbell AP, Fry AM.

Clin Infect Dis. 2015 Jun 1;60(11):1677-80. doi: 10.1093/cid/civ146. Epub 2015 Feb 25.

40.

Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015.

Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, McLean HQ, Belongia EA, Gaglani M, Berman L, Foust A, Sessions W, Thaker SN, Spencer S, Fry AM; Centers for Disease Control and Prevention.

MMWR Morb Mortal Wkly Rep. 2015 Jan 16;64(1):10-5.

41.

Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility.

Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS.

J Infect Dis. 2015 May 15;211(10):1519-28. doi: 10.1093/infdis/jiu650. Epub 2014 Nov 21.

42.

Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type.

McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, Piedra PA, Zimmerman RK, Nowalk MP, Raviotta JM, Jackson ML, Jackson L, Ohmit SE, Petrie JG, Monto AS, Meece JK, Thaker SN, Clippard JR, Spencer SM, Fry AM, Belongia EA.

J Infect Dis. 2015 May 15;211(10):1529-40. doi: 10.1093/infdis/jiu647. Epub 2014 Nov 18.

43.

Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season.

Havers F, Thaker S, Clippard JR, Jackson M, McLean HQ, Gaglani M, Monto AS, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Flannery B, Thompson MG, Fry AM.

Clin Infect Dis. 2014 Sep 15;59(6):774-82. doi: 10.1093/cid/ciu422. Epub 2014 Jul 16.

44.

Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons.

Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE.

J Infect Dis. 2014 Dec 1;210(11):1792-9. doi: 10.1093/infdis/jiu327. Epub 2014 Jun 6.

45.

Factors associated with influenza vaccine receipt in community dwelling adults and their children.

Malosh R, Ohmit SE, Petrie JG, Thompson MG, Aiello AE, Monto AS.

Vaccine. 2014 Apr 1;32(16):1841-7. doi: 10.1016/j.vaccine.2014.01.075. Epub 2014 Feb 12.

46.

Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.

Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, Jackson L, Meece JK, Nowalk MP, Song J, Zervos M, Cheng PY, Rinaldo CR, Clipper L, Shay DK, Piedra P, Monto AS.

Clin Infect Dis. 2014 Feb;58(3):319-27. doi: 10.1093/cid/cit736. Epub 2013 Nov 13.

47.

Influenza transmission in a cohort of households with children: 2010-2011.

Petrie JG, Ohmit SE, Cowling BJ, Johnson E, Cross RT, Malosh RE, Thompson MG, Monto AS.

PLoS One. 2013 Sep 25;8(9):e75339. doi: 10.1371/journal.pone.0075339. eCollection 2013.

48.

Influenza vaccine effectiveness in the community and the household.

Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS.

Clin Infect Dis. 2013 May;56(10):1363-9. doi: 10.1093/cid/cit060. Epub 2013 Feb 14.

49.

Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains.

Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breese Hall C, Monto AS, Griffin MR, Belongia E, Shay DK; US Flu-VE Network.

Clin Infect Dis. 2012 Oct;55(7):951-9. Epub 2012 Jul 25.

50.

Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection.

Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS.

J Infect Dis. 2011 Dec 15;204(12):1879-85. doi: 10.1093/infdis/jir661. Epub 2011 Oct 12.

PMID:
21998477

Supplemental Content

Loading ...
Support Center